Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 5/20 | 0.47 |
| ▸ | PNMT | P11086 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9422769 | 1.00 | FDPS (0.47) | FDPSIDO1PNMTTAAR1SIGMAR1 | |
| SCHEMBL9130780 | 1.00 | FDPS (0.47) | FDPSIDO1PNMTTAAR1SIGMAR1 | |
| SCHEMBL12215710 | 0.81 | SLC6A2 (0.61) | FDPSIDO1PNMTTAAR1SIGMAR1 | |
| SCHEMBL9776061 | 0.78 | PNMT (0.49) | FDPSIDO1PNMTTAAR1SIGMAR1 | |
| SCHEMBL139768 | 0.77 | FDPS (0.46) | FDPSIDO1PNMTTAAR1SIGMAR1 | |
| SCHEMBL11251872 | 0.77 | FDPS (0.58) | FDPSIDO1PNMTTAAR1SIGMAR1 | |
| SCHEMBL74006 | 0.77 | IDO1 (0.52) | FDPSIDO1PNMTTAAR1SIGMAR1 | |
| SCHEMBL9775967 | 0.76 | MAPT (0.64) | FDPSIDO1PNMTTAAR1TSHR | |
| Cericlamine SCHEMBL114233 | 0.76 | FDPS (0.45) | FDPSIDO1PNMTTAAR1SIGMAR1 | |
| Cericlamine SCHEMBL29359640 | 0.76 | FDPS (0.45) | FDPSIDO1PNMTTAAR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5348980-A | Antihistamines, antiallergens | INSTITUTE DE RECHERCHE JOUVEINAL (FR) | 1994-09-20 | — | — | US | claimed |
| US-4994617-A | Analgesics | JOUVEINAL S.A. (FR) | 1991-02-19 | — | — | US | claimed |
| EP-0237366-B1 | AMINO ALCOHOLS, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATIONS, IN PARTICULAR FOR THEREPEUTICAL USE | JOUVEINAL S.A. (FR) | 1989-04-26 | — | — | EP | claimed |
| EP-0237366-A1 | Amino alcohols, process for their preparation and their applications, in particular for therepeutical use | JOUVEINAL S.A. (FR) | 1987-09-16 | — | — | EP | claimed |
| JP-6025117-A | — | — | None | — | — | JP | disclosed |
| JP-6025117-A | — | — | None | — | — | JP | disclosed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2218442-A1 | Methods, compositions, and kits for the treatment of ophthalmic disorders | CombinatoRx, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20100081713-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | CombinatoRx, (Singapore) Pte. Ltd. | 2010-04-01 | — | — | US | disclosed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | disclosed |
| US-6121491-A | Process for the preparation of (+/-)3-(3,4-dichlorophenyl)-2-dimethylamino-2-methylpropan-1-OL or cericlamine (INN) | WARNER-LAMBERT COMPANY (US) | 2000-09-19 | — | — | US | disclosed |
| US-5348980-A | Antihistamines, antiallergens | INSTITUTE DE RECHERCHE JOUVEINAL (FR) | 1994-09-20 | — | — | US | disclosed |
| US-5348980-A | Antihistamines, antiallergens | INSTITUTE DE RECHERCHE JOUVEINAL (FR) | 1994-09-20 | — | — | US | disclosed |
| JP-H0625117-A | NEW ENATIOMER DERIVED FROM (S)-2-AMINO-2-(3,4-DICHLOROBENZYL)-1-PROPANOL | INST DE RECH JOUVEINAL | 1994-02-01 | — | — | JP | disclosed |
| JP-H0625117-A | NEW ENATIOMER DERIVED FROM (S)-2-AMINO-2-(3,4-DICHLOROBENZYL)-1-PROPANOL | INST DE RECH JOUVEINAL | 1994-02-01 | — | — | JP | disclosed |
| US-4994617-A | Analgesics | JOUVEINAL S.A. (FR) | 1991-02-19 | — | — | US | disclosed |
| EP-0237366-B1 | AMINO ALCOHOLS, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATIONS, IN PARTICULAR FOR THEREPEUTICAL USE | JOUVEINAL S.A. (FR) | 1989-04-26 | — | — | EP | disclosed |
| EP-0237366-A1 | Amino alcohols, process for their preparation and their applications, in particular for therepeutical use | JOUVEINAL S.A. (FR) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081713-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | IFNG, IL5, HAVCR2 | FDPS 3463/4885IDO1 115/4885PNMT 3480/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | FDPS 308/4885IDO1 73/4885PNMT 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.